Tesamorelin and Sermorelin Together: What Is Known
Tesamorelin and Sermorelin taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 12 results, 2 Oct 2026).
Side by side
Showing 7 of 13 fields where the two differ. Class, Category, PCAC vote, Jul 2026, WADA, Anti-doping detection, Evidence strength are the same or both unknown.
| Field | Tesamorelin | Sermorelin |
|---|---|---|
| Class | GHRH analog | GHRH analog |
| Also called | tesa, Egrifta | — |
| Category | Growth hormone | Growth hormone |
| FDA status | FDA approved (Egrifta) | Compounded by prescription |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption. | Prohibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. |
| Anti-doping detection |
|
|
| Half-life | 11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR) | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101 | Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 1992, PMID 1379256 |
| Human studies we summarised | 12 human (11 randomized or controlled) of 16 summarised | 6 human (1 randomized or controlled) of 9 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg, 20 mg | 2 mg, 5 mg, 9 mg, 15 mg |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026) | Not in the letters we track |
Tesamorelin vs Sermorelin
Choosing between the two rather than combining them? The comparison lines them up field by field.
Two GHRH analogues with different regulatory fates
WADA lists both in the same prohibited class, growth hormone-releasing hormone and its analogues, alongside CJC-1295.[2]
Tesamorelin is approved: Egrifta WR is indicated for excess abdominal fat in HIV-infected adults with lipodystrophy.[5]
Sermorelin is not currently approved. FDA's database shows only discontinued Geref records.[19]
Tesamorelin is a 44-amino-acid growth-hormone-releasing factor analogue with a hexenoyl group added at the N-terminus, a modification that distinguishes it from native GHRH.[5]
Evidence on each, side by side
Tesamorelin's flagship trial randomised 412 patients; abdominal fat on CT was the primary endpoint.[16]
Sermorelin's largest study was a multicenter open-label trial in previously untreated children with growth hormone deficiency.[17]
In healthy older men, GHRH treatment did not change weight, BMI, waist-to-hip ratio or DEXA measures of muscle and fat.[11]
A PubMed search on 2 Oct 2026 for sermorelin with tesamorelin matched 12 records.
Calculated from pubmed query (sermorelin[tiab] OR Geref[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]); records matched 12; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date
Anti-doping detection work
One anti-doping method paper studied the in vitro metabolism and detection in fortified urine of four GHRH analogs: sermorelin, tesamorelin, CJC-1295, and CJC-1295 with drug affinity complex.[4]
That paper notes there is evidence of their use but they do not appear to have been found in samples by accredited anti-doping labs.[4]
The Egrifta label asks for glucose to be evaluated before treatment and monitored periodically afterwards.[5]
Common questions
Can you take tesamorelin and sermorelin together?
This page cites no trial of both. The Egrifta WR label says GH may alter the clearance of compounds metabolized by CYP450 liver enzymes.[5]
Tesamorelin vs sermorelin: what is the difference?
Per its label, tesamorelin (Egrifta WR) is a GHRF analog indicated for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and is not indicated for weight loss management.[5]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 5EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 7Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 8The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 9Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
- 10Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
- 11Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
- 12PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 17Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
- 18PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 19Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.